Glioblastoma stem cells as a new therapeutic target for glioblastoma

Clinical Medicine Insights: Oncology

Volumn 9, Issue , 2015, Pages 95-103

  Kalkan, Rasime ^a  

^a NEAR EAST UNIVERSITY   (Turkey)

Author keywords

Glioblastoma stem cell; Hypoxia; Mutation; Stem cell; Therapy

Indexed keywords

BMI1 PROTEIN; BONE MORPHOGENETIC PROTEIN; CD133 ANTIGEN; CD15 ANTIGEN; EPIDERMAL GROWTH FACTOR; HEAT SHOCK PROTEIN 90; HYPOXIA INDUCIBLE FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOCITRATE DEHYDROGENASE 1; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MYC PROTEIN; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SONIC HEDGEHOG PROTEIN; STAGE SPECIFIC EMBRYO ANTIGEN 1; STAT PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; WNT PROTEIN;

ARTICLE; ASTROCYTE; CANCER GROWTH; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL HYPOXIA; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELL THERAPY; EPIGENETICS; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE SILENCING; GLIOBLASTOMA; GLIOBLASTOMA STEM CELL; HUMAN; NERVE CELL; NONHUMAN; OLIGODENDROGLIA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 84948981558     PISSN: None     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S30271     Document Type: Article

References (63)

1. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle. 2009;8(20):3274-84.
2. Cho D, Lin S, Yang W, et al. Targeting cancer stem cells for treatment of glioblastoma multiforme. Cell Transplant. 2013;22:731-9.
3. Kanno H, Miyake S, Nakanowatari S. Signaling pathways in glioblastoma cancer stem cells: a role of Stat3 as a potential therapeutic target. Austin J Cancer Clin Res. 2015;2(2):1030.
4. Stopschinski BE, Beier CP, Beier D. Glioblastoma cancer stem cells-From concept to clinical application. Cancer Lett. 2013;338:32-40.
5. Cruceru ML, Neagu M, Demoulin JB, Constantinescu SN. Therapy targets in glioblastoma and cancer stem cells: lessons from hematopoietic neoplasm. J Cell Mol Med. 2013;17(10):1218-35.
6. Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S. Cancer stem cells in glioblastoma-molecular signaling and therapeutic targeting. Protein Cell. 2010;1(7):638-55.
7. Gilbert CA, Ross AH. Glioma stem cells: cell culture, markers and targets for new combination therapies. J Cell Biochem. 2009 Dec 1;108(5):1031-8.
8. Schiffer D, Mellai M, Annovazzi L, et al. Stem cell niches in glioblastoma: a neuropathological view. Biomed Res Int. 2014;2014:725921.
9. Masson N, Ratcliffe PJ. Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer Metab. 2014;2014(2):3.
10. Metallo CM, Gameiro PA, Bell EL, et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature. 2011;481(7381):380-4.
11. Pistollato F, Abbadi S, Rampazzo E, et al. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. Stem Cells. 2010;28:851-62.
12. Piccirillo SG, Combi R, Cajola L, et al. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene. 2009;28:1807-11.
13. Tafani M, Di Vito M, Frati A, et al. Proinflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J Neuroinflammation. 2011;8:32.
14. Persana L, Rampazzo E, Basso G, Viola G. Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting. Biochem Pharmacol. 2013;85:612-22.
15. Dahlrot RH, Hermansen SK, Hansen S, Kristensen BW. What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Pathol. 2013;6(3):334-48.
16. Singh SK, Hawkins CI, Clarke D, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
17. Son MJ, Woolard K, Nam DH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009;4:440-52. [cell surface markers were used].
18. Nakano I. Stem cell signature in glioblastoma: therapeutic development for a moving target. J Neurosurg. 2015;122(2):324-30.
19. Kerr MA, Stocks SC. The role of CD15-(Le(X))-related carbohydrates in neutrophil adhesion. Histochem J. 1992;24:811-26.
20. Capela A, Temple S. LeX/ssea-1 is expressed by adult mouse CNS stem cells, identifying them as nonependymal. Neuron. 2002;35:865-75.
21. Capela A, Temple S. LeX is expressed by principle progenitor cells in the embryonic nervous system, is secreted into their environment and binds Wnt-1. Dev Biol. 2006;291:300-13.
22. Reifenberger G, Sieth P, Niederhaus M, Wechsler W. Expression of CD15 in tumours of the nervous system. Histochem J. 1992;24:890-901.
23. Brescia P, Richichi C, Pelicci G. Current strategies for identification of glioma stem cells: adequate or unsatisfactory? J Oncol. 2012;2012:376894.
24. Bresvia P, Richichi C, Pelicci G. Identification of glioma stem cells: what is already known and how far do still need to go? The biomarkers dilemma. J Carcinog Mutagen. 2011;S1:003.
25. Horisawa K, Yanagawa H. Musashi proteins in neural stem/progenitor cells. In: Dr. Tao Sun, ed. Neural Stem Cells and Therapy. InTech; 2012. Available at http://www.intechopen.com/books/neural-stem-cells-and-therapy/musashi-proteins-in-eural-stem-progenitor-cells.
26. MSI1 musashi RNA-binding protein 1 [Homo sapiens (human)] Gene ID: 4440, updated on February 1, 2015.
27. Bayin NS, Modrek AS, Placantonakis DG. Glioblastoma stem cells: molecular characteristics and therapeutic implications. World J Stem Cells. 2014;6(2):230-8.
28. Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol. 2010;80:654-65.
29. Garner JM, Fan M, Yang CH, et al. Constitutive activation of signal transducer and activator of transcription 3 (STAT3) and nuclear factor κB signaling in glioblastoma cancer stem cells regulates the Notch pathway. J Biol Chem. 2013;288:26167-76.
30. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274-93.
31. Kahn J, Hayman TJ, Jamal M, et al. The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro Oncol. 2014;16(1):29-37.
32. Banerji U, Dean EJ, Gonzalez M, et al. First-in-human phase I trial of the dual mTORC1 and mTORC2 inhibitor AZD2014 in solid tumors. J Clin Oncol. 2012;30(suppl):abstr3004.
33. Jackson SE. Hsp90: structure and function. Top Curr Chem. 2012;2013(328):155-240.
34. Uzzaman M, Keller G, Germano IM. In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas. Neuro Oncol. 2009;11(2):102-8.
35. Kwiatkowska A, Nandhu MS, Behera P, Chiocca EA, Viapiano MS. Strategies in gene therapy for glioblastoma. Cancers (Basel). 2013;5(4):1271-305.
36. Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G, Pelicci G. CD133 is essential for glioblastoma stem cell maintenance. Stem Cells. 2013;31(5):857-69.
37. Herrlinger U, Woiciechowski C, Sena-Esteves M, et al. Neural precursor cells for delivery of replication-conditional hsv-1 vectors to intracerebral gliomas. Mol Ther. 2000;1:347-57.
38. Häyry V, Tynninen O, Haapasalo HK, et al. Stem cell protein BMI-1 is an independent marker for poor prognosis in oligodendroglial tumours. Neuropathol Appl Neurobiol. 2008;34:555-63.
39. Chen YC, Chang CJ, Hsu HS, et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol. 2010;46:158-65.
40. Kato H, Fujimura M, Kumabe T, Ishioka C, Kanamaru R, Yoshimoto T. PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. J Clin Neurosci. 2004;11:37-41.
41. Yang YP, Chien Y, Chiou GY, et al. Inhibition of cancer stem cell-like properties and reduced chemoradioresistance of glioblastoma using micro RNA145 with cationic polyurethane-short branch PEI. Biomaterials. 2012;33:1462-76.
42. Tobias AL, Thaci B, Auffinger B, et al. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Stem Cells Transl Med. 2013;2(9):655-66.
43. Kaluzova M, Bouras A, Machaidze R, Hadjipanayis CG. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab conjugated in iron-oxide nanoparticles. Oncotarget. 2015;6:8788-806.
44. Lee JY, Lee DH, Kim HA, et al. Double suicide gene therapy using human neural stem cells against glioblastoma: double safety measures. J Neurooncol. 2014;116(1):49-57.
45. Cheng L, Wu Q, Huang Z, et al. L1CAM regulates DNA damage checkpoint response of glioblastoma stem cells through NBS1. EMBO J. 2011;30(5):800-13.
46. Lathia JD, Gallagher J, Myers JT, et al. Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One. 2011;6(9):e24807.
47. Galli R, Binda E, Orfanelli U, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64(19):7011-21.
48. Clarke RH, Moosa S, Anzivino M, et al. Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia. PLoS One. 2014;9(10):e111199.
49. Furnari FB, Fenton T, Bachoo RM, et al. Malignant astrocytic glioma: genetics, biology and paths to treatment. Genes Dev. 2007;21:2683-710.
50. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359:492-507.
51. Combs ES, Rieken S, Wick W, et al. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back? Radiat Oncol. 2011;13(6):115.
52. Kalkan R, Atli Eİ, Özdemir M, et al. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme. Gene. 2015;554(1):81-6.
53. Eramo A, Ricci-Vitiani L, Zeuner A, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 2006;13:1238-41.
54. Beier D, Rohrl S, Pillai DR, et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 2008;68:5706-15.
55. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.
56. Bralten LB, Kloosterhof NK, Balvers R, et al. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol. 2011;69:455-63.
57. Lai A, Kharbanda S, Pope WB, et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29(34):4482-90.
58. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 2007;67:4010-5.
59. Campos B, Zeng L, Daotrong PH, et al. Expression and regulation of AC133 and CD133 in glioblastoma. Glia. 2011;59:1974-86.
60. Gambelli F, Sasdelli F, Manini I, et al. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression. Cell Biol Int. 2012;36:29-38.
61. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmelan AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br J Cancer. 2010;102:789-95.
62. Yang L, Lin C, Wang L, Guo H, Wang X. Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res. 2012;318(19):2417-26.
63. Li P, Zhou C, Xu L, Xiao H. Hypoxia enhances stemness of cancer stem cells in glioblastoma: an in vitro study. Int J Med Sci. 2013;10(4):399-407.